Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products.
The last earnings update was 51 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Sangui Biotech International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sangui Biotech International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sangui Biotech International. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Sangui Biotech International's
is considered below, and whether this is a fair price.
Price based on past earnings
Sangui Biotech International's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sangui Biotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Sangui Biotech International
expected to grow at an
Unable to compare Sangui Biotech International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Sangui Biotech International's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Sangui Biotech International's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Sangui Biotech International is high growth as no earnings estimate data is available.
Unable to determine if Sangui Biotech International is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sangui Biotech International's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Sangui Biotech International
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Sangui Biotech International's finances.
The net worth of a company is the difference between its assets and liabilities.
Sangui Biotech International's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Sangui Biotech International has no long term commitments.
This treemap shows a more detailed breakdown of
Sangui Biotech International's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Sangui Biotech International has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Thomas Striepe has been the Chief Executive Officer of Sangui Biotech International Inc., since April 8, 2008 and serves as its Chief Financial Officer. Mr. Striepe serves as the Vice President of Accounting and Controlling at Dr. Ludz GmbH, Hamburg, Germany, a financial services company. He served as Member of the Management Board at Feedback AG since 2005 until December 31, 2015. He is responsible for various group financial statements and the development and building of reporting and planning systems. He served as Member of the Management Board of Dr. Ludz Verm gensberatungs -und Vermittlungsgesellschaft mbH from 2004. He held management positions in the accounting departments of several German and international corporations. He has been a Non-Executive Director of Sangui Biotech International Inc., since February 7, 2005. He served as President at Sangui Biotech International, Inc. Mr. Striepe obtained MBA from Hamburg University. From 1982 to 1988, Mr. Striepe studied Business Management, majoring in Accounting and Taxes in Hamburg.
Thomas's compensation has increased whilst company is loss making.
Thomas's remuneration is lower than average for companies of similar size in Germany.
CEO, CFO & Executive Director
Board of Directors
CEO, CFO & Executive Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through Internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.